Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma-MedSci.cn

Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma

Lordick, F; Chao, J; Buxo, E; van Laarhoven, HWM; Lima, CMR; Lorenzen, S; Dayyani, F; Heinemann, V; Greil, R; Stienen, S; Shitara, K

ANNALS OF ONCOLOGY, 2020; 31 (): S928

科室
- - 订阅+
  - 更多科室
工具
服务